Full Text View
Tabular View
No Study Results Posted
Related Studies
Switching Medication to Treat Schizophrenia
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by National Institute of Mental Health (NIMH).   Recruitment status was  Active, not recruiting

First Received on September 3, 2002.   Last Updated on September 18, 2008   History of Changes
Sponsor: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00044655
  Purpose

This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.


Condition Intervention Phase
Schizophrenia
 Drug: Risperidone
Drug: Olanzapine
Drug: Ziprasidone
Drug: Quetiapine
Drug: Aripiprazole
 Phase IV

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effectiveness of Switching Antipsychotic Medications

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
Drug Information available for: Risperidone Quetiapine Quetiapine fumarate Ziprasidone hydrochloride Aripiprazole Olanzapine Ziprasidone Ziprasidone mesylate
U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • Time to medication discontinuation [ Time Frame: Measured at Year 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Psychiatric symptoms, hospitalization, and medication side effects [ Time Frame: Measured at Year 1 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: July 2001
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Stay
Participants will continue taking medication prescribed at study entry
 Drug: Risperidone
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Risperdal, Risperdal Consta
Drug: Olanzapine
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Zyprexa
Drug: Ziprasidone
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Geodon
Drug: Quetiapine
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Seroquel
Drug: Aripiprazole
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Abilify
Active Comparator: Switch
Participants will change medications from medication prescribed at study entry
 Drug: Risperidone
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Risperdal, Risperdal Consta
Drug: Olanzapine
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Zyprexa
Drug: Ziprasidone
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Geodon
Drug: Quetiapine
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Seroquel
Drug: Aripiprazole
As prescribed by routine prescriber (not dictated by study protocol)
Other Name: Abilify

Detailed Description:

Over the past several years, new, "atypical" antipsychotic medications have become available to treat schizophrenia with little information to guide prescribing for relatively stable outpatients.

Participants will be randomly assigned to either continue taking their current medications for schizophrenia, or to switch to a new medication. Participants assigned to switch to a new medication will begin receiving either olanzapine (Zyprexa), risperidone (Risperdal), ziprasidone (Geodon), quetiapine (Seroquel), or aripiprazole (Abilify), depending on what they are currently taking. Participants currently taking a single oral medication will switch to olanzapine, risperidone, ziprasidone, quetiapine, or aripiprazole. Participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone (Risperdal Consta). Participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using. Participants will stay on their assigned treatment for 6 months, after which time the participant's prescribing psychiatrist will advise the participant on which medication should be used. Study participants are interviewed at study start and at follow-up visits for 1 year.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • SCID diagnosis of schizophrenia or schizoaffective disorder
  • Partially remitted outpatients, defined as persons who have received clear symptomatic benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy or inability to tolerate an efficacious dose) or suffer significant side effects
  • Treatment with antipsychotic medications for at least 2 months
  • Received at least 1 outpatient mental health service every 3 months for the past 6 months

Exclusion criteria:

  • Severe symptoms or side effects that indicate the necessity for a medication change
  • Currently taking 3 or more antipsychotic medications for ongoing daily administration (PRN medications and mood stabilizers are allowable)
  • Treatment with clozapine
  • One or more nights spent in a psychiatric hospitalization within the past 3 months
  • Received services from a crisis intervention program within the past 3 months
  • Require placement in a skilled nursing facility as a result of a physical condition or disability
  • Criminal charges pending (once charges clear, the person will be considered)
  • Pregnant or breast feeding
  • Contraindication to any of the medications to which the patient might be assigned
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00044655

Locations
United States, Connecticut
State of Connecticut Department of Mental Health and Addiction Services Outpatient Mental Health Centers
Hartford, Connecticut, United States, 06134
Yale University School of Medicine
New Haven, Connecticut, United States, 06519
United States, Florida
Mental Health Advocates, Inc.
Boca Raton, Florida, United States, 33432
University of Miami
Miami, Florida, United States, 33136
United States, Maryland
Clinical Insights
Glen Burnie, Maryland, United States, 21061
United States, Massachusetts
Dr. John C. Corrigan Community Mental Health Center
Fall River, Massachusetts, United States, 02720
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01605
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55454
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Bronx VA Medical Center
Bronx, New York, United States, 10468
United States, North Carolina
John Umstead Hospital
Butner, North Carolina, United States, 27509
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
United States, Pennsylvania
VA Medical Center, University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75235
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
United States, Washington
VA Puget Sound Health Care System
Tacoma, Washington, United States, 98493
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Study Chair: Susan M. Essock, PhD Columbia University College of Physicians and Surgeons
  More Information

No publications provided by National Institute of Mental Health (NIMH)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702-8. Epub 2011 May 2.

Responsible Party: Susan M. Essock, PhD/Director, Department of Mental Health Services and Policy Research, New York State Psychiatric Institute and Columbia University
ClinicalTrials.gov Identifier: NCT00044655     History of Changes
Other Study ID Numbers: R01 MH59312, DSIR AT-SP
Study First Received: September 3, 2002
Last Updated: September 18, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Risperidone
Ziprasidone
Quetiapine
Olanzapine
Aripiprazole
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
 Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on February 12, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services